Astrana Health Inc 2024年度报告

(Mark One) OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934for the transition period from___ to ___.Commission file number:001-37392 Astrana Health, Inc. (Exact name of registrant as specified in its charter) 1668 S. Garfield Avenue,2nd Floor,Alhambra,California91801(Address of principal executive offices, including zip code)Registrant’s telephone number, including area code:(626)282-0288Securities registered pursuant to Section 12(b) of the Act: Name of Each Exchange on Which RegisteredThe Nasdaq Stock Market LLC (Title of class) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.Yes☒No☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.Yes☐No☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file suchreports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. ☒Accelerated filer☐Smaller reporting companyEmerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of theeffectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) bythe registered public accounting firm that prepared or issued its audit report.☒ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of theregistrant included in the filing reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-basedcompensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).☐Yes☒No The aggregate market value of common stock held by non-affiliates of the registrant, as of June 28, 2024, the last day of theregistrant’s most recently completed second fiscal quarter, was approximately$1.7billion(based on the closing price for shares ofthe registrant’s common stock as reported by the Nasdaq Stock Market on June 28, 2024). As of March 6, 2025, there were56,252,503shares of common stock of the registrant, $0.001 par value per share, issued andoutstanding, which includes 6,132,802 treasury shares that are owned by Allied Physicians of California, a Professional MedicalCorporation d.b.a. Allied Pacific of California IPA (“APC”), a consolidated affiliate of Astrana Health, Inc. These shares arelegally issued and outstanding but treated as treasury shares for accounting purposes. DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive Proxy Statement for the 2025 annual meeting of the stockholders of the registrant areincorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such Proxy Statementwill be filed with the Securities and Exchange Commission (the “SEC”) within 120 days of the registrant’s fiscal year endedDecember 31, 2024. Astrana Health, Inc.Form 10-KFiscal Year Ended December 31, 2024 Table of Contents PageITEMIntroductory Note4Note About Forward-Looking Statements5 ITEM 5Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of EquitySecurities65ITEM 6[Reserved]66ITEM 7Management’s Discussion and Analysis of Financial Condition and Results of Operations67ITEM 7AQuantitative and Qualitative Disclosures About Market Risk87ITEM 8Financial Statements and Supplementary Data88ITEM 9Changes in and Disagreements with Accountants on Accounting and Financial Disclosure152ITEM 9AControls and Proced